Subunit formulations are regarded as the safest type of vaccine, but they often contain a protein-based antigen that can result in significant challenges, such as preserving antigenicity during formulation and administration. Many studies have demonstrated that encapsulation of protein antigens in polymeric microparticles (MPs) via emulsion techniques results in total IgG antibody titers comparable to alum formulations, however, the antibodies themselves are non-neutralizing. To address this issue, a coaxial electrohydrodynamic spraying (electrospray) technique is used to formulate a microparticulate-based subunit anthrax vaccine under conditions that minimize recombinant protective antigen (rPA) exposure to harsh solvents and high shear stress. rPA and the adjuvant resiquimod are encapsulated either in separate or the same acetalated dextran MPs. Using a murine model, the electrospray formulations lead to higher IgG2a subtype titers as well as comparable total IgG antibody titers and toxin neutralization relative to the FDA-approved vaccine (BioThrax). BioThrax provides no protection against a lethal inhalational challenge of the highly virulent Ames Bacillus anthracis anthrax strain, whereas 50% of the mice vaccinated with separately encapsulated electrospray MPs survive. Overall, this study demonstrates the potential use of electrospray for encapsulating protein antigens in polymeric MPs.
Coaxial electrohydrodynamic spraying (electrospray) is used to encapsulate a protein antigen from Bacillus anthracis in acetalated dextran microparticles under benign processing conditions. Immunizing with this electrospray formulation results in comparable toxin neutralizing activity and substantially enhanced protection relative to the FDA-approved anthrax vaccine. The study establishes electrospray as an effective technique to encapsulate protein antigens in polymeric microparticles.
http://ift.tt/2bRoEjn
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου